CHEK2 and neoplasm: It is worth noting that Irofulven (MGI-114), a new cytotoxic anticancer drug with DNA damaging and MAPK activating properties, can also promote tumour cell apoptosis via ATM/CHK2 activation in the presence of BRCA1 [74–77].